Browsing by Author "Gelabert-Baldrich, Mariona"

Sort by: Order: Results:

  • Cid-Samper, Fernando; Gelabert-Baldrich, Mariona; Lang, Benjamin; Lorenzo Gotor, Maria de las Nieves; Ponti, Riccardo delli; Severijnen, Lies-Anne W.F.M.; Bolognesi, Benedetta; Gelpi, Ellen; Hukema, Renate K.; Botta Orfila, Teresa; Tartaglia, Gian Gaetano (Elsevier, 2018)
    Recent evidence indicates that specific RNAs promote the formation of ribonucleoprotein condensates by acting as scaffolds for RNA-binding proteins (RBPs). We systematically investigated RNA-RBP interaction networks to ...
  • Sampera Borràs, Aïda, 1990-; Sánchez-Martín, Francisco Javier; Arpí Llucià, Oriol; Visa Turmo, Laura; Iglesias Coma, Mar; Menéndez, Silvia; Gaye, Élisabeth; Dalmases Massegú, Alba, 1982-; Clavé Safont, Sergi; Gelabert-Baldrich, Mariona; Tuxen Poulsen, Thomas; Kragh, Michael; Bellosillo Paricio, Beatriz; Albanell Mestres, Joan; Rovira Guerín, Ana; Rovira Guerín, Ana; Montagut Viladot, Clara (American Association for Cancer Research (AACR), 2019)
    Despite the clinical benefit of trastuzumab, eventually all HER2-amplified gastric cancer tumors develop drug resistance. We aimed to identify molecular mechanisms of acquired resistance to trastuzumab in gastric cancer ...
  • Sanchez Martin, Francisco Javier; Bellosillo Paricio, Beatriz; Gelabert-Baldrich, Mariona; Dalmases Massegú, Alba, 1982-; Cañadas Castillo, Israel, 1984-; Vidal Barrull, Joana; Martinez, Alejandro; Argiles, Guillem; Visa Turmo, Laura; Arpí Llucià, Oriol; Iglesias García, Mar; Rovira Guerín, Ana; Albanell Mestres, Joan; Tabernero Cartula, Josep; Montagut Viladot, Clara (American Association for Cancer Research, 2016)
    PURPOSE: Approved anti-EGFR antibodies cetuximab and panitumumab provide significant clinical benefit in patients with metastatic colorectal cancer (MCRC). However, patients ultimately develop disease progression, often ...